Thor Medical Enters Partnership with Eckert & Ziegler to Enable Access of Lead-212 for the Pharmaceutical Industry

28 May 2026 07:00 CEST

28.5.2026 07:00:01 CEST | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading emerging supplier of alpha-emitters for next-generation
precision cancer treatment, today signed a collaboration and supply agreement
with Eckert & Ziegler, a world-leading specialist in isotope-related components,
equipment and services for nuclear medicine and radiation therapy.

The partnership will accelerate the development of lead-212 (Pb-212) based
therapies by strengthening the supply and manufacturing base for the isotope,
thereby supporting the growing number of biotech and pharmaceutical companies
developing lead-212 based therapies.

Due to its favorable in-body chemistry, rapid clearance profile and suitability
for theranostic applications, lead-212 has emerged as one of the most promising
isotopes in targeted alpha therapy. Under the terms of the agreement, Thor
Medical will initially supply lead-212 to Eckert & Ziegler for preclinical
research and development. Both companies will also explore how to further
integrate their complementary capabilities in isotope production and
radiopharmaceutical manufacturing, with the aim of scaling up production
capacity over time.

"This collaboration reflects a strategic alignment between Thor Medical and
Eckert & Ziegler. It lays out how our isotope supply and technology can be
embedded within leading development and manufacturing platforms, expanding our
presence through Eckert & Ziegler's impressive global network. Together, we are
well positioned to support the continued growth of the radiopharmaceutical
market by enabling more lead-212 based assets to advance from early research
into formal development programs," said Jasper Kurth, Chief Executive Officer of
Thor Medical.

Thor Medical's technology platform has been developed and validated through
pilot operations at Herøya Industrial Park since early 2024 with product sales
and delivery to leading industry players since 2025. Thor Medical is currently
commissioning its first commercial production facility, AlphaOne, which is
expected to commence production in the third quarter of 2026.

"Eckert & Ziegler has proven itself as a reliable enabler for the
radiopharmaceutical industry. When an isotope like lead-212 has the potential to
open up new therapeutic avenues, we are taking responsibility in this area. Thor
Medical has quietly built a leading technology platform and strong production
capabilities for high-purity medical isotopes and precursor materials, making
the company a strong strategic fit. We look forward to further strengthening our
position as an integrated radiopharmaceutical one-stop-shop through this
collaboration", said Dr. Harald Hasselmann, Chief Executive Officer of Eckert &
Ziegler SE.

Eckert & Ziegler combines radioisotope supply with fully integrated
radiopharmaceutical research, development and manufacturing services. Their
GMP-compliant CDMO services bridge the gap for biotech and pharma firms lacking
necessary in-house radiopharmaceutical production capabilities.



ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium, a key component of next-generation targeted cancer
treatment. Its proprietary production process requires no irradiation or use of
nuclear reactors, and provides a reliable, environmentally friendly and
cost-efficient supply of alpha emitters to the radiopharmaceutical industry.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by fueling
next-generation cancer therapies with high-purity isotopes. Thor Medical is
headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the
ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com - https://www.thormedical.com.



About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in
isotope-related components for nuclear medicine and radiation therapy. The
company offers a broad range of services and products for the
radiopharmaceutical industry, from early development work to contract
manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are
listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.



For further information, please contact:

Thor Medical ASA

Mathias Nilsen Reierth, Head of Communications and Corporate Affairs

+47 988 05 724, mathias.reierth@thormedical.com

Eckert & Ziegler SE
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com - https://www.ezag.com/

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18923015/10957/Download%20announc
ement%20as%20PDF.pdf

More information:
Access the news on Oslo Bors NewsWeb site

674683_Download announcement as PDF.pdf